Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Androxy and Arimidex in ER-/PR- Metastatic Breast Cancer
NCT00303615Phase 2Terminated
- Sponsor
- Legacy Health
- Start
- Jun 2005
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluoxymesterone in breast cancer, sponsored by Legacy Health. Primary endpoint: Time to disease progression. Started Jun 2005; status: terminated.
02
Drugs
fluoxymesterone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00303615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00303615.